CS MEDICA Announces Strategic Partnerships to Enhance Funding

Securing New Capital and Strengthening Shareholder Relations Through Strategic Collaborations

CS MEDICA, a pioneering MedTech company specializing in pain management and autoimmune diseases with innovative substance-based medical devices containing bioactive CBD, announces a direct issue of 1.5 MDKK with Börsjakten AB at a share price of 3.00 DKK. This initiative is part of our broader strategy to secure short-term capital while preparing for a larger funding round, pending approval at the upcoming EGM. Additionally, we are excited to unveil three strategic collaborations aimed at enhancing shareholder engagement and increasing market capitalization.

Börsjakten AB Collaboration: This partnership will launch a stock competition, "Börsjakten," to attract new shareholders and boost publicity and awareness through influential finance and economics influencers.

IPO Invest Sweden AB Partnership: This collaboration focuses on enhancing CS MEDICA's investor relations strategy to strengthen shareholder value and engagement.

Novtec AB Agreement: Novtec AB will assist in securing investment capital ensuring CS MEDICA has the necessary funds for strategic growth initiatives.

These partnerships underscore CS MEDICA's commitment to innovation, growth, and delivering value to stakeholders.